These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35078863)

  • 1. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
    Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
    J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.
    Marken J; Muralidharan S; Giltiay NV
    Arthritis Res Ther; 2021 Jan; 23(1):5. PubMed ID: 33407802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
    Samant M; Ziemniak J; Paolini JF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
    Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
    Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.
    Brams P; Black A; Padlan EA; Hariharan K; Leonard J; Chambers-Slater K; Noelle RJ; Newman R
    Int Immunopharmacol; 2001 Feb; 1(2):277-94. PubMed ID: 11360929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases.
    Wu HH; Ralph KL; Sepuldeva E; Hansen G; Li H; Huang ZF; Liu D; Dziegelewski M; Ahlberg J; Frego L; Fogal S; van Tongeren S; Grimaldi C; Litzenberger T; Presky D; Singh S; Brodeur S; Kroe-Barrett R
    Int J Pharm; 2021 Nov; 609():121162. PubMed ID: 34624444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody.
    Ristov J; Espie P; Ulrich P; Sickert D; Flandre T; Dimitrova M; Müller-Ristig D; Weider D; Robert G; Schmutz P; Greutmann B; Cordoba-Castro F; Schneider MA; Warncke M; Kolbinger F; Cote S; Heusser C; Bruns C; Rush JS
    Am J Transplant; 2018 Dec; 18(12):2895-2904. PubMed ID: 29665205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
    Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys.
    Nicholson SM; Casey KA; Gunsior M; Drabic S; Iverson W; Cook H; Scott S; O'Day T; Karanth S; Dixit R; Ryan PC
    Br J Pharmacol; 2020 Mar; 177(5):1061-1076. PubMed ID: 31648370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys.
    Ulrich P; Flandre T; Espie P; Sickert D; Rubic-Schneider T; Shaw DA; Rush JS
    Toxicol Sci; 2018 Nov; 166(1):192-202. PubMed ID: 30099540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
    Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
    Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.
    Resetkova E; Kawai K; Enomoto T; Arreaza G; Togun R; Foy TM; Noelle RJ; Volpé R
    Thyroid; 1996 Aug; 6(4):267-73. PubMed ID: 8875745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.
    Okimura K; Maeta K; Kobayashi N; Goto M; Kano N; Ishihara T; Ishikawa T; Tsumura H; Ueno A; Miyao Y; Sakuma S; Kinugasa F; Takahashi N; Miura T
    Am J Transplant; 2014 Jun; 14(6):1290-9. PubMed ID: 24731050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
    Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
    Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys.
    Boon L; Laman JD; Ortiz-Buijsse A; den Hartog MT; Hoffenberg S; Liu P; Shiau F; de Boer M
    Toxicology; 2002 May; 174(1):53-65. PubMed ID: 11972992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.
    Tang T; Cheng X; Truong B; Sun L; Yang X; Wang H
    Pharmacol Ther; 2021 Mar; 219():107709. PubMed ID: 33091428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
    Komocsar WJ; Blackbourne JL; Halstead CA; Winstead CJ; Wierda D
    J Immunotoxicol; 2016; 13(1):7-19. PubMed ID: 25585959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
    Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
    Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.